Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed No phase listed Observational

Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

ClinicalTrials.gov ID: NCT03045120

Public ClinicalTrials.gov record NCT03045120. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 16, 2026, 6:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Study identification

NCT ID
NCT03045120
Recruitment status
Completed
Study type
Observational
Phase
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Enrollment
118 participants

Conditions and interventions

Interventions

Not listed

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 18, 2017
Primary completion
Jun 19, 2022
Completion
Jun 19, 2022
Last update posted
Dec 20, 2022

2017 – 2022

United States locations

U.S. sites
24
U.S. states
13
U.S. cities
21
Facility City State ZIP Site status
Mount Sinai Hospital Chicago Illinois 60608
Alexian Brothers Medical Center Elk Grove Village Illinois 60007
The Cancer Institute At Alexian Brothers Elk Grove Village Illinois 60007
Northwest Oncology & Hematology, SC Hoffman Estates Illinois 60169
Hematology/Oncology Of The North Shore Lake Forest Illinois 60045
Northwest Oncology & Hematology, SC Rolling Meadows Illinois 60008
Healthcare Research Network III, LLC Tinley Park Illinois 60487
American Health Network Avon Indiana 46123
Cancer Center Of Kansas Wichita Kansas 67214
Hazard Arh Regional Medical Center Hazard Kentucky 41701
St. Agnes Hospital Baltimore Maryland 21229
St Vincent Frontier Cancer Center Billings Montana 59102
Local Institution - 0009 Hackensack New Jersey 07601
Roswell Park Cancer Institute Buffalo New York 14263
Weill Med Col Of Cornell New York New York 10021
Columbia University Medical Center (Cumc) New York New York 10032
Memorial Sloan Kettering Cancer Center New York New York 10065
Montefiore Medical Center The Bronx New York 10467
Leo W.Jenkins Cancer Center Greenville North Carolina 27834
Oncology Hematology Care Cincinnati Ohio 45202
Oregon Health & Science University Portland Oregon 97239
Huntsman Cancer Hospital Salt Lake City Utah 84093
Providence Regional Cancer Partnership Everett Washington 98201
Fred Hutchinson Can Res Ctr Seattle Washington 98109

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03045120, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 20, 2022 · Synced May 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03045120 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →